Gilead, CymaBay Therapeutics receive US antitrust clearance for their deal
Gilead Sciences’ proposed acquisition of California-based CymaBay Therapeutics for $4.3 billion has received antitrust clearance from the US authorities. The waiting period under the Hart-Scott-Rodino Act expired on March 8, the...To view the full article, register now.
Already a subscriber? Click here to view full article